Differing clinical features between Japanese siblings with cerebrotendinous xanthomatosis with a novel compound heterozygous CYP27A1 mutation: a case report.
CTX
CYP27A1
Case report
Chenodeoxycholic acid
Cholestanol
Journal
BMC neurology
ISSN: 1471-2377
Titre abrégé: BMC Neurol
Pays: England
ID NLM: 100968555
Informations de publication
Date de publication:
25 May 2022
25 May 2022
Historique:
received:
24
04
2021
accepted:
10
05
2022
entrez:
25
5
2022
pubmed:
26
5
2022
medline:
28
5
2022
Statut:
epublish
Résumé
Cerebrotendinous xanthomatosis (CTX) is an autosomal-recessive lipid storage disorder caused by mutations in the CYP27A1 gene encoding the key enzyme in the bile acid synthesis, sterol 27-hydroxylase. Here, we report two Japanese CTX siblings with a novel compound heterozygous CYP27A1 mutation, showing different clinical phenotypes and responses to chenodeoxycholic acid (CDCA) therapy. The proband, a 32-year-old man, who had chronic diarrhea, bilateral cataracts, and xanthomas, demonstrated progressive neurological manifestations including ataxia, and spastic paraplegia during a 5-year follow-up period despite normalization of serum cholestanol after initiation of CDCA treatment. He also exhibited cognitive decline although improvement had been observed at the beginning of treatment. Follow-up brain magnetic resonance imaging (MRI) revealed pronounced progressive atrophy in the cerebellum, in addition to expanding hyperintense lesions in the dentate nuclei, posterior limb of the internal capsule, cerebral peduncles, and inferior olives on T2-weighted images. In contrast, the two-year-younger sister of the proband presented with chronic diarrhea, cataracts, xanthomas, and intellectual disability but no other neurological symptoms at the time of diagnosis. CDCA treatment lead to improvement of cognitive function and there were no characteristic CTX-related MRI features during the follow-up period. The siblings shared a paternally inherited c.1420C > T mutation (p.Arg474Trp) and a maternally inherited novel c.1176_1177delGA mutation, predicting p.(Glu392Asp*20). Our cases suggest that early diagnosis and subsequent initiation of CDCA treatment are crucial before the appearance of characteristic MRI findings and severe neurological manifestations related to CTX. Further studies are required to elucidate mechanisms responsible for the clinical diversity of CTX and prognostic factors for long-term outcomes following initiation of CDCA treatment.
Sections du résumé
BACKGROUND
BACKGROUND
Cerebrotendinous xanthomatosis (CTX) is an autosomal-recessive lipid storage disorder caused by mutations in the CYP27A1 gene encoding the key enzyme in the bile acid synthesis, sterol 27-hydroxylase. Here, we report two Japanese CTX siblings with a novel compound heterozygous CYP27A1 mutation, showing different clinical phenotypes and responses to chenodeoxycholic acid (CDCA) therapy.
CASE PRESENTATION
METHODS
The proband, a 32-year-old man, who had chronic diarrhea, bilateral cataracts, and xanthomas, demonstrated progressive neurological manifestations including ataxia, and spastic paraplegia during a 5-year follow-up period despite normalization of serum cholestanol after initiation of CDCA treatment. He also exhibited cognitive decline although improvement had been observed at the beginning of treatment. Follow-up brain magnetic resonance imaging (MRI) revealed pronounced progressive atrophy in the cerebellum, in addition to expanding hyperintense lesions in the dentate nuclei, posterior limb of the internal capsule, cerebral peduncles, and inferior olives on T2-weighted images. In contrast, the two-year-younger sister of the proband presented with chronic diarrhea, cataracts, xanthomas, and intellectual disability but no other neurological symptoms at the time of diagnosis. CDCA treatment lead to improvement of cognitive function and there were no characteristic CTX-related MRI features during the follow-up period. The siblings shared a paternally inherited c.1420C > T mutation (p.Arg474Trp) and a maternally inherited novel c.1176_1177delGA mutation, predicting p.(Glu392Asp*20).
CONCLUSIONS
CONCLUSIONS
Our cases suggest that early diagnosis and subsequent initiation of CDCA treatment are crucial before the appearance of characteristic MRI findings and severe neurological manifestations related to CTX. Further studies are required to elucidate mechanisms responsible for the clinical diversity of CTX and prognostic factors for long-term outcomes following initiation of CDCA treatment.
Identifiants
pubmed: 35614401
doi: 10.1186/s12883-022-02711-4
pii: 10.1186/s12883-022-02711-4
pmc: PMC9131546
doi:
Substances chimiques
Chenodeoxycholic Acid
0GEI24LG0J
CYP27A1 protein, human
EC 1.14.15.15
Cholestanetriol 26-Monooxygenase
EC 1.14.15.15
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
193Informations de copyright
© 2022. The Author(s).
Références
Brain. 2000 May;123 ( Pt 5):908-19
pubmed: 10775536
J Inherit Metab Dis. 2018 Jul;41(4):647-656
pubmed: 29484516
Neurol Sci. 2017 Mar;38(3):481-483
pubmed: 27888347
J Inherit Metab Dis. 2017 Nov;40(6):771-781
pubmed: 28980151
Eur J Med Genet. 2012 Jan;55(1):71-4
pubmed: 21958693
Orphanet J Rare Dis. 2014 Nov 26;9:179
pubmed: 25424010
J Clin Lipidol. 2018 Sep - Oct;12(5):1169-1178
pubmed: 30017468
Eur J Neurol. 2011 Oct;18(10):1203-11
pubmed: 21645175
Eur J Pediatr. 1998 Apr;157(4):313-6
pubmed: 9578968
J Inherit Metab Dis. 2014 May;37(3):421-9
pubmed: 24442603
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
J Neurol. 2019 Aug;266(8):2043-2050
pubmed: 31115677
Neurology. 1996 Feb;46(2):571-4
pubmed: 8614539
J Hum Genet. 2018 Mar;63(3):271-280
pubmed: 29321515
J Biol Chem. 1991 Apr 25;266(12):7779-83
pubmed: 2019602
J Neurol. 2017 May;264(5):862-874
pubmed: 28324197
Clin Neuropharmacol. 2013 May-Jun;36(3):78-83
pubmed: 23673909
N Engl J Med. 1984 Dec 27;311(26):1649-52
pubmed: 6504105
Neurology. 2019 Jan 8;92(2):e83-e95
pubmed: 30530799
Neurol Sci. 2006 Jun;27(2):143-9
pubmed: 16816916